Quick Answer
Palomino Laboratories Inc. reported Diluted EPS of $0.47 per share (loss) for fiscal year 2025.
Palomino Laboratories Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.47 | -4181.8% |
| 2024 | -$0.01 | +35.3% |
| 2023 | -$0.02 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.54 | — | -5900.0% |
| June 30, 2025 | -$0.01 | -50.0% | +25.0% |
| March 31, 2025 | -$0.01 | -20.0% | — |
| September 30, 2024 | $0.00 | +100.0% | +100.0% |
| June 30, 2024 | -$0.01 | -500.0% | +40.0% |
| March 31, 2024 | -$0.01 | -900.0% | -11.1% |
| September 30, 2023 | -$0.01 | -800.0% | -800.0% |
| June 30, 2023 | -$0.00 | — | +0.0% |
- Palomino Laboratories Inc. showed a decrease of -4181.8% in Diluted EPS compared to the prior fiscal year.
- Over the 2023–2025 period, Palomino Laboratories Inc.’s diluted eps has declined by 2670.6% (from $0.02 per share (loss) to $0.47 per share (loss)).
- The most recent figure is from Palomino Laboratories Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: